Did Your National Securities Broker Recommend MannKind Corp (MNKD)?
Did your National Securities broker recommend MannKind Corp (MNKD) stock to you? If so, National Securities may be liable for losses, because the firm had a reasonable obligation to supervise its brokers. If it does not, it can be held liable for losses in the Financial Industry Regulatory Authority (FINRA) arbitration forum on a contingency fee basis. MNKD is a biopharmaceutical company, focusing on the discovery, development and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and 2 diabetes. It is headquartered in Westlake Village, California and was founded in 1991. Many brokers overconcentrated investments in MNKD, and their customers suffered losses because of this. If you or someone you know was one of these customers, please call 312–332–4200 today to speak to one of our attorneys for free. There is no obligation with the call. Attorneys are standing by. We take cases on a contingency fee basis only.